Rajkotupdates.news : zydus needle free corona vaccine zycov d – Covid-19 cases are under control, especially after the aggressive vaccination drives. Embracing the new normal, schools have reopened, with children thrilled at meeting their friends, physically sitting in the classrooms, and enjoying some time away from home. The government has approved some vaccines already being given to children.
After initially approving only ZyCov-D, the government of India has approved another vaccine, Corbevax, to boost the vaccination drive, in addition to Covaxin, which first agree upon for teens in India. The increasing number of approved vaccines from different manufacturers has rapidly vaccinated children against Covid-19.
What is the ZyCoV-D COVID19 vaccine?
First, it developed the ZyCoV-D vaccine in India, and is the first DNA-based COVID-19 vaccine available to humans, including children over 12 years of age and adults. Developed the vaccine jointly with the Department of Biotechnology (DBT) and distributed it under the banner of ‘Mission COVID Suraksha’ operated by DBT’s PSU, BIRAC.
There are currently no DNA vaccines approved for use in humans. However, several DNA vaccines are undergoing human clinical trials, and our regulatory agencies have already approved several DNA vaccines. The efficacy rate of vaccines based on DNA plasmid technology is 66.66%. ZyCoV-D was originally a three-dose vaccine given 3 to 4 weeks apart. And also but a two-dose regimen is now approved.
ZyCoV-D is a plasmid DNA vaccine that, when administered, induces the production of the SARS-CoV-2 viral spike protein. This immune response mediates by the cellular and humoral arms of the human immune system and is essential for disease prevention and viral elimination. The Ahmedabad-based pharmaceutical giant claims that its plasmid DNA platform’s plug-and-play technology can easily modify to handle viral mutations, including those already present.
How to administer the vaccine without a needle?
The vaccine administers using a needleless injector that injects a small fluid flow through the skin into a target tissue depth. The Company claims the technology can eliminate the risk of needlestick injuries while significantly reducing potential adverse effects. People with hallucinophobes, characterized by an irrational fear of blood or needles, may also benefit.
The Drugs Control General of India (DCGI) received an application from Cadila Healthcare on July 1, 2021 requesting permission to use the vaccine only for specific and time-sensitive emergencies. On August 20, 2021, the Central Drug Standards Organization (CDSCO) Committee of Subject Matter Experts recommended that DCGI grant the request, and DCGI followed their advice.
The ZyCoV-D COVID-19 Vaccine indicates to prevent COVID-19, the disease caused by the SARS-CoV-2 virus. ZyCoV-D showed robust immunogenicity, acceptability, and safety profile in earlier adaptive Stage I/II scientific trials. In addition, an independent Data Safety Monitoring Board has monitored
the Phase I/II and Phase III clinical trials. As a result, India authorized ZyCoV-D COVID-19 Vaccine for adolescents older than 12.
The journal Nature says, vaccine heralds a wave of DNA vaccines for various diseases undergoing clinical trials worldwide.’ In addition, the JAMA Network published an article on October 12, 2021 – India’s New COVID-19 DNA Vaccine for Adolescents and Adults Is a First. The vaccine contains plasmid DNA, circular strands of genetic material that enter the host cells’ nuclei, where converted into mRNA. The mRNA then travels out of the seats into the cytoplasm and is translated into the SARS-CoV-2 spike protein.
In April 2022, health minister Dr. Mansukh Mandaviya said the Central Drugs Standard Control Organization authorized two doses of ZyCoV-D for those above 12.
In a tweet posted on January 16, 2022, Union Health Minister Mansukh Mandaviya stated that over 3.5 crore teens in the 15-18 age group had received the first vaccine dose of Covid-19 vaccines since January 3. Two Covid-19 vaccines have the Indian government’s approval for children (12+), Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCoV-D.
Zydus-d manufactures the drug substance for the needle-free DNA Plasmid vaccine, ZyCoV-D. The manufacturing process and in-process material transfers within the plant are automatic. Zydus has also entered into a final agreement with Shilpa Medicare Limited, a contract manufacturing organization, to produce mutually agreeable doses of ZyCoV- D. The Company also contracted with Enzychem Lifesciences of the Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine.
On April 26, 2022, the DCGI authorized a two-dose regimen which will now administer on days 0 and 28. Previously, its approved as a triple dose on day 0, day 28, and day 56, for a total of 6 mg. A two-dose regimen for using a 3 mg dose was equivalent to the current three-dose regimen in a clinical trial. Previous clinical trials conducted dosage reviews.
ZyCoV-D Side Effects
A study published by The Lancet EClinical Medicine on July 16, 2021. And also found that most solicited AEs reported were after the first dose of the vaccine. And also while the second and third doses of vaccination were well-tolerated. The ZyCoV-D Phase 1 safety data further suggests that the vaccine could be a safe booster as there was no increase in the frequency of side effects after the third dose compared to the first. And also an essential aspect of the safety profile of SARS-CoV-2 vaccines.
In addition, one attractive feature of DNA vaccines, like corona vaccine zycov d, is that the immunizations could boost without significant limitations such as dosing-incremented toxicities or anti-vector responses. Therefore, the ZyCoV-D vaccine is safe, well-tolerated, and immunogenic in the Phase 1 trial.
ZyCoV-D is stored at 2-8 C but shows good stability at temperatures of 25oC for at least three months. The thermostability of the vaccine will help in easy transportation and storage and reduce any cold chain breakdown challenges leading to vaccine wastage.
Media reported in India that the vaccine costs 265 rupees ($3.53) per dose. And also, the applicator offers 93 rupees per dose, excluding GST.
ZyCoV-MV, COVID-19 Vaccine Candidate
Zydus Cadila has also developed a live, attenuated recombinant measles virus-vectored vaccine, ZyCoV-MV, to provide long-term immunity from COVID-19.
Zydus Cadila Financial News 2022
February 3, 2022 – Zydus announced for the third quarter ended December 31, 2021, Zydus reported consolidated revenues of Rs.3655 crores. Earnings before Interest, Depreciation, and Tax raised at Rs. 753 crores. Net Profit for the sector stood at Rs. 500 crores.
ZyCoV-D is India’s first DNA vaccine against the COVID-19 virus. We reported on “rajkotupdates.news: zydus needle free corona vaccine zycov d” and discussed its innovation. In this blog, we talked about ZyCoV-D. And also simple chemical explanation, and how to administer the vaccine. We also spoke about the approvals and distributions we received. And also zycov d mentioned and expanded upon in this blog.